Safety and Effectiveness of Weekly Carfilzomib

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide ...

This trial suggests that carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy may be safe and tolerable and is associated with high rates of ...

The MANHATTAN Nonrandomized Clinical Trial - PubMed

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple ...

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide ...

Meaning. This trial suggests that carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy may be safe and tolerable and is ...

Safety and effectiveness of weekly carfilzomib ... - Synapse

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly ...

Full article: Efficacy and safety of weekly carfilzomib (70 mg/m2 ...

Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and ...

study demonstrated that once-weekly carfilzomib (70 mg/m2) in combination with dexamethasone (Kd70) was safe and more effective with a convenient dosing regimen ...

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail ...

Conclusions: Once-weekly Kd70 resulted in PFS benefits vs twice-weekly Kd27 with a favorable benefit/risk profile regardless of frailty score as ...

Once-weekly versus twice-weekly carfilzomib in patients with newly ...

Once-weekly 70 mg/m carfilzomib as induction and maintenance therapy for newly diagnosed multiple myeloma patients was as safe and effective as twice-weekly 36 ...

Safety and Effectiveness of Weekly Combination Carfilzomib ...

The overall response rate was 100%, with a very good partial response rate of 95%. The estimated 1-year progression-free survival rate was 98%, ...

Comparative Efficacy and Safety of Once Versus Twice Weekly ...

Carfilzomib use as a single agent or in combination has been shown to improve outcomes in relapsed refractory multiple myeloma (RRMM).

Comparative Efficacy and Safety of Once Versus Twice Weekly ...

Carfilzomib use as a single agent or in combination has been shown to improve outcomes in relapsed refractory multiple myeloma (RRMM).

Once- versus twice-weekly carfilzomib in relapsed and refractory ...

Safety profiles by bortezomib-refractory status were comparable to the overall population. Once-weekly Kd70 mg/m2 demonstrated improved efficacy ...

Once weekly versus twice weekly carfilzomib dosing in patients with ...

Overall safety was comparable between the groups. Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen ...

An observational study of once-weekly carfilzomib in patients with ...

Aim: To describe the treatment patterns, effectiveness and safety of wKd therapy in real-world settings in Japan. Methods: We investigated data ...

Carfilzomib, thalidomide, and dexamethasone are safe and effective ...

The overall response rate was 88% (73% had a very good partial response or better). There was no difference in the depth of response, progression-free survival ...

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail ...

The grade ≥3 acute renal failure rates for QW Kd70 and BIW Kd27 were 0 and 5% for fit pts, 7 and 6% for int pts, and 4 and 7% for frail pts, respectively. The ...

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide ...

There were no deaths. Conclusions and relevance: In this nonrandomized clinical trial, carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy ...

Secondary Analysis from the CHAMPION-1 Study by Prior Lines of ...

Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the ...

Clinical Trials Using Carfilzomib - NCI

The combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone may be a safe and effective treatment when given to patients with relapsed ...

Real-world effectiveness and safety analysis of carfilzomib ...

Before KRd, 99% of patients had received bortezomib (54% were refractory disease), and 82% had received lenalidomide (57% were refractory ...